Sanofi-Regeneron's $1B IL-13/IL-4 Bet: Long-Acting Differentiation Thesis Meets Crowded, Payer-Disciplined Market

Sanofi and Regeneron Expand Immunology Alliance with New Antibodies

Sanofi and Regeneron have expanded their longstanding antibody collaboration, adding multiple next-generation, long-acting immunology antibodies to their alliance. This includes REGN20423, an IL-13 monoclonal antibody currently in Phase 1 for atopic dermatitis, a long-acting IL-4xIL-13 bispecific, and two other preclinical antibodies. Under the agreement, Regeneron will receive a $1 billion upfront payment from Sanofi, with potential for up to an additional $7 billion in future milestone payments. The companies will equally share development and commercialization costs, as well as future profits globally for these new programs, with Regeneron leading R&D and Sanofi leading commercial efforts.

• The expanded alliance introduces four new long-acting antibodies to the pipeline. These include REGN20423, an IL-13 monoclonal antibody currently in a Phase 1 clinical study for atopic dermatitis, a long-acting IL-4xIL-13 bispecific antibody, and two other long-acting preclinical antibodies targeting IL-4 and IL-4Rα. These additions aim to build upon the success of Dupixent in treating diseases driven by type 2 inflammation.
• The financial terms of the agreement involve a significant upfront payment of $1 billion from Sanofi to Regeneron. Additionally, Regeneron stands to receive up to an extra $7 billion in potential development, regulatory, and commercial milestone payments. Both companies will equally share the costs associated with developing and commercializing these new programs, and will split any future profits from these potential products 50:50 on a global basis.
• The collaboration outlines a clear division of responsibilities, with Regeneron taking the lead on research and development activities for the newly added antibodies, leveraging its scientific discovery expertise. Sanofi will be responsible for leading the global commercialization efforts for these potential products. Furthermore, Regeneron has an option to include Sanofi’s investigational bispecific Nanobody® VHH therapy, lunsekimig, in the collaboration once it completes its Phase 3 studies for chronic obstructive pulmonary disease.

Addressing Persistent Challenges in Atopic Dermatitis Treatment

Atopic dermatitis (AD) presents a complex therapeutic landscape shaped by chronic disease course, heterogeneous patient populations, and the limitations of both established and emerging treatment modalities. Despite meaningful advances in targeted therapies, several persistent challenges continue to complicate long-term disease management across age groups and severity spectra.

• Corticosteroid-associated systemic risks in long-term use: Continuous use of moderate- to high-potency topical corticosteroids over several months can contribute to Cushing's syndrome, HPA axis suppression, growth retardation, and reduced bone density — particularly in pediatric patients. This necessitates careful monitoring of growth, development, and cortisol levels in children on long-term topical corticosteroid treatment, and underscores the need for steroid-sparing strategies.

• Treatment discontinuation and unsatisfactory therapeutic effect: In a 1-year controlled study of 713 pediatric AD patients, the discontinuation rate in the conventional treatment group reached 51.5% at 12 months versus 31.6% in the pimecrolimus group, with unsatisfactory therapeutic effect cited as the primary driver (30.4% vs. 12.4%). Proportionately more patients with severe or very severe disease discontinued in the conventional arm, highlighting the inadequacy of standard regimens for higher-severity disease.

• Nonresponse and loss of efficacy with targeted agents: A subset of patients receiving dupilumab are either partial responders — exhibiting some improvement in Investigator's Global Assessment score but not sufficient to meet the primary endpoint — or non-durable responders who achieve therapeutic endpoint with subsequent partial loss of efficacy. For upadacitinib 15 mg, higher baseline EASI, IgE, TARC, LDH, NLR, CRP, SII, and SIRI may predict primary nonresponse, while prior systemic dupilumab or corticosteroid use may predict secondary nonresponse.

• Adverse events with biologics and JAK inhibitors, particularly in the elderly: For dupilumab, real-world data identified higher-than-SmPC incidence rates for eosinophilia, blepharitis, dry eyes, head and neck erythema, non-infectious conjunctivitis, and meibomian gland dysfunction. In elderly AD patients, the incidence of serious adverse events with JAK inhibitors abrocitinib and upadacitinib increased and was dose-related, warranting further study and verification in this population.

• Ocular adverse events limiting biologic tolerability: Eye symptoms occurred in 43.1% of dupilumab-treated patients in one real-world cohort, with 16.3% developing conjunctivitis. While a history of conjunctivitis on dupilumab is not a contraindication to initiating tralokinumab, ocular adverse events remain a clinically meaningful tolerability concern that can influence treatment selection and continuity.

• Local tolerability and adherence barriers with topical calcineurin inhibitors: Skin burning was the most common causally-related adverse event with 0.1% tacrolimus ointment (31.7%), followed by pruritus (11.3%), folliculitis (6.4%), and herpes simplex (5.7%) over 24 months of treatment. Poor percutaneous penetration of tacrolimus further limits therapeutic efficiency, and transient irritation symptoms — including burning sensation and feelings of warmth or heat — represent a recognized barrier to patient adherence.

• Evidence gaps in disease modification and early intervention: Whether disease-modifying therapies used as an early interventional approach impact disease course and comorbidity development in AD is not well-understood. Despite early data suggesting that both the choice and timing of early intervention can affect long-term disease course, studies in AD remain lacking, and more research is needed to extend early results to a more inclusive set of comorbidities and longer-term outcomes.

Navigating the Evolving Atopic Dermatitis Treatment Landscape

The atopic dermatitis (AD) treatment landscape has undergone substantial expansion beyond traditional topical corticosteroids, with multiple mechanistically distinct agents now supported by robust clinical trial data. Among topical therapies, the nonsteroid classes — topical calcineurin inhibitors (pimecrolimus and tacrolimus) and the PDE4 inhibitor crisaborole — have demonstrated efficacy in lesion clearance and symptom management across 69 identified clinical trials, with low systemic absorption and no demonstrated increased risk of malignancy or systemic adverse events. More recently, topical 1.5% ruxolitinib cream, a selective JAK1/JAK2 inhibitor, has been evaluated in a network meta-analysis of 12 randomized controlled trials and shown no statistically significant differences versus systemic agents — including dupilumab, upadacitinib, and abrocitinib — for IGA 0/1, EASI-75, and Itch NRS4 in patients aged ≥ 12 years with moderate AD eligible for systemic therapy, with point estimates numerically favoring ruxolitinib cream for IGA 0/1 and EASI-75.

In the systemic space, dupilumab has accumulated an expanding evidence base across age groups, from children as young as 6 months through adolescents and adults. In children aged 6 months to 5 years, a phase 3 open-label extension demonstrated that by week 52, 36.2% achieved IGA 0/1, and 96.6%, 79.3%, and 58.6% achieved at least 50%, 75%, and 90% improvement in EASI scores, respectively. In adolescents, 52-week data showed EASI improvements of −85% ± 12% (2 mg/kg) and −84% ± 20% (4 mg/kg) from baseline. The IL-13 inhibitor tralokinumab has also demonstrated progressive, sustained benefit over 1 year: in a pooled post hoc analysis of ECZTRA 1 and 2, EASI-75 response rates improved from 37.6% to 61.8% and EASI-90 from 20.4% to 37.3% with continued treatment from week 16 to week 52. Real-world data from a single-center retrospective study of 37 adults further showed that 93% (28/30) achieved IGA 0/1 at 1 year of tralokinumab treatment, with no adverse events reported through follow-up.

The oral JAK inhibitors — upadacitinib, abrocitinib, and baricitinib — have introduced a rapidly acting systemic option, though with a differentiated safety profile relative to dupilumab. A post hoc analysis of the phase 3 JADE COMPARE trial demonstrated that abrocitinib 200 mg achieved significantly greater IGA 0/1, EASI-75, and EASI-90 responses versus placebo (nominal p < 0.05) across all severe and/or difficult-to-treat AD subgroups, with time to PP-NRS4 response of 4.5–6.0 days. A population-based cohort study of 938 propensity score-matched patients per arm found that oral JAKi were associated with significantly higher risks of skin and subcutaneous tissue infection (HR = 1.35, 95% CI = 1.07–1.69), herpes simplex (HR = 1.64, 95% CI = 1.03–2.61), herpes zoster (HR = 2.51, 95% CI = 1.14–5.52), acne (HR = 2.09, 95% CI = 1.54–2.84), and cytopenia — including neutropenia (HR = 4.02, 95% CI = 1.91–8.47) — compared with dupilumab, without increased risks of mortality, malignancy, major adverse cardiovascular events, or venous thromboembolism. Pharmacovigilance analyses using the FAERS database further confirmed herpes zoster as the most frequent infection-related adverse event for both upadacitinib and abrocitinib, while also identifying novel signals including sepsis, appendicitis, and septic shock, underscoring the importance of ongoing long-term surveillance as these agents become more widely adopted.

Next-Gen Antibodies: Sanofi and Regeneron's Strategic Immunology Play

The expanded collaboration between Sanofi and Regeneron marks a significant strategic move, signaling a deepened commitment to innovation within the immunology landscape. By focusing on next-generation antibody technologies, specifically long-acting and bispecific formats, the companies are positioning themselves to address persistent challenges in chronic inflammatory diseases such as atopic dermatitis (AD).

The rationale behind developing long-acting antibodies is clear: to enhance patient convenience and adherence. Existing treatments for AD, like dupilumab, have demonstrated remarkable and sustained efficacy over several years, yet studies consistently highlight the need for continuous treatment to maintain clinical benefit, with many patients experiencing relapse upon discontinuation. A long-acting formulation, as seen with other antibodies engineered for prolonged half-life, could significantly reduce the burden of frequent dosing, thereby improving the patient experience.

Furthermore, the pursuit of bispecific antibodies represents an exciting frontier in therapeutic development. Research indicates that dual targeting of inflammatory pathways can offer enhanced anti-inflammatory potency compared to single monoclonal antibodies. This approach aims to overcome the 'therapeutic ceiling' often encountered with monotherapies by simultaneously blocking multiple, potentially synergistic, disease-driving mechanisms. For instance, an IL-4xIL-13 bispecific antibody could offer a more comprehensive blockade than a single agent, building on the success of existing IL-4/IL-13 inhibitors.

However, this ambitious strategy is not without its considerations. The market for AD is increasingly competitive, with dupilumab setting a high standard for long-term efficacy and safety. Any new therapy will need to demonstrate clear clinical differentiation or a superior patient experience to carve out a significant niche. The development of bispecific antibodies also introduces complexities in manufacturing and potential for unexpected safety profiles due to their dual mechanism of action, necessitating rigorous clinical evaluation. While long-acting antibodies promise convenience, their extended presence requires careful assessment of sustained efficacy and potential for long-term adverse events. This collaboration, backed by substantial investment, underscores a bold vision to redefine treatment paradigms in immunology, but success will hinge on navigating these scientific and clinical hurdles.